The abstract is read at the publisher; the summary is JClub's.
Selective PET imaging ligands and receptor-specific muscarinic medications (including KarxT/Cobenfy) are poised to advance clinical translation for substance use disorder treatments targeting M1, M4, and M5 receptors.
- Why it matters: Muscarinic acetylcholine receptors in meso-cortico-limbic circuits modulate dopamine, glutamate, and GABA signaling, but most evidence for substance use disorders remains preclinical.
- What they did: Preclinical knockout and drug-consumption paradigms indicate that lacking M1/M4 and M5 receptors changes drug intake in opposite directions, and drug exposure shifts receptor expression (downregulating M1/M4 and upregulating M5).
- The result: With new selective PET ligands and medications targeting specific muscarinic receptors, clinical translational research can more directly test receptor-linked mechanisms in substance use disorder treatment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.